高级搜索
季晓君, 苗雷, 马昌友, 唐莹, 周秋华, 吴舰, 徐丹. 消化系统常见肿瘤突变基因分析及新靶点成药性评估[J]. 肿瘤防治研究, 2022, 49(4): 340-346. DOI: 10.3971/j.issn.1000-8578.2022.21.0938
引用本文: 季晓君, 苗雷, 马昌友, 唐莹, 周秋华, 吴舰, 徐丹. 消化系统常见肿瘤突变基因分析及新靶点成药性评估[J]. 肿瘤防治研究, 2022, 49(4): 340-346. DOI: 10.3971/j.issn.1000-8578.2022.21.0938
JI Xiaojun, MIAO Lei, MA Changyou, TANG Ying, ZHOU Qiuhua, WU Jian, XU Dan. Mutation Genes in Common Tumors of Digestive System and Druggability of New Targets[J]. Cancer Research on Prevention and Treatment, 2022, 49(4): 340-346. DOI: 10.3971/j.issn.1000-8578.2022.21.0938
Citation: JI Xiaojun, MIAO Lei, MA Changyou, TANG Ying, ZHOU Qiuhua, WU Jian, XU Dan. Mutation Genes in Common Tumors of Digestive System and Druggability of New Targets[J]. Cancer Research on Prevention and Treatment, 2022, 49(4): 340-346. DOI: 10.3971/j.issn.1000-8578.2022.21.0938

消化系统常见肿瘤突变基因分析及新靶点成药性评估

Mutation Genes in Common Tumors of Digestive System and Druggability of New Targets

  • 摘要:
    目的 通过对消化系统常见肿瘤的突变基因进行分析,建立抗肿瘤药物新靶点的成药性评估方法。
    方法 搜集Integrative Onco Genomics数据库中5种消化系统常见肿瘤(食管癌、胃癌、结直肠癌、肝癌以及胰腺癌)的突变基因数据,从中筛选出各肿瘤中突变率较高的基因,通过canSAR数据库对这些基因或其编码的蛋白进行成药性评估,找到可用于抗肿瘤新药开发的潜在靶点。
    结果 本研究搜集了5种肿瘤共计35个队列,5445个肿瘤样品。选择每个肿瘤突变率排名前10的基因进一步分析,使用canSAR数据库对未公开研究的突变基因或其编码的蛋白质进行成药性分析,共筛选到17个可成药的潜在药物治疗靶点。
    结论 本研究建立了一种基于突变基因或其编码蛋白的靶点成药性评估方法,该方法的运用能够为寻找新的抗肿瘤药物治疗靶点提供参考,节省新药开发中靶点筛选的成本与时间。

     

    Abstract:
    Objective To establish a druggability evaluation method for new targets of anti-tumor drugs by analyzing the mutation genes of common tumors in the digestive system.
    Methods We collected the mutant gene data of the five common tumors of the digestive system (esophageal cancer, gastric cancer, colorectal cancer, liver cancer and pancreatic cancer) in the Integrative Onco Genomics database, and screened out the genes with higher mutation rates in each tumor. We evaluated the druggability of these genes or their encoded proteins, and discovered the potential targets for the new anti-tumor drugs.
    Results A total of five tumors, 35 cohorts and 5445 tumor samples were collected in this study. The top 10 mutation genes were selected for further analysis. The canSAR database was used to analyze the druggability of unpublished mutant genes or their encoded proteins, and a total of 17 potential therapeutic drug targets were screened out.
    Conclusion A method for evaluating druggability of targets based on mutant genes or their encoded protein is established in this study. The application of this method can provide a reference for discovering new anti-tumor therapeutic target, saving the cost and time of target screening in new drug development.

     

/

返回文章
返回